Aisha A Alhaddad

For correspondence:-     Email: aahaddad@taibahu.edu.sa   Tel:+966-581234555

Received: 11 June 2024        Accepted: 4 October 2024        Published: 30 October 2024

Citation: Alhaddad AA. Overview of pharmacology and clinical development of small interfering RNA. Trop J Pharm Res 2024; 23(10):1779-1790 doi: 10.4314/tjpr.v23i10.24

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Nanocarrier-based delivery of small interfering RNA (siRNA) has been recognized as a promising approach in cancer treatment. To produce siRNA, short nucleotide sequences are generated exogenously. siRNA inhibits target gene expression in a sequence-specific manner and initiates RNA interference (RNAi) in cells. SiRNA is a recently popularized nucleic acid-based medication that shows unique promise in the treatment of cancer. Before clinical siRNA delivery devices are created, there are still a lot of challenges to be solved. This review covers the potential targets for siRNA drug design, elucidates the characteristics and advantages of siRNA drugs and provides a summary of the available clinical siRNA therapies for cancer treatment. Therapeutically complex siRNA chemical alterations and delivery systems are described, and bio-responsive materials for siRNA release have been classified. This study will support continued advancements in clinical applications of siRNA by acting as a resource for disseminating information for more accurate and effective targeted delivery systems.